News blog

N4 Pharma

  • BY: Andrew Hore |
  • POSTED: 22/04/2019 |

N4 Pharma says that recent formulation work for Nuvec has demonstrated inconsistencies with previous studies and the share price has nearly halved in the past fortnight. 

Nuvec is a potential nanoparticle drug delivery technology. The in vitro tests produced positive results but this was not replicated in in vivo tests. Further experiments will be undertaken in order to define protocols and methodology to ensure that the tests are standardised.

News about further studies should be available by the end of the summer.

There should be enough cash to last until the end of 2019, thanks to a recent £1m placing at 10p a share.  The current share price is 4.15p.

© 2019 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

News Blog
All micro news

Quoted Micro 22 July 2019

Continue reading... | 22/07/2019

UniVision Engineering Ltd

CCTV technology supplier UniVision Engineering Ltd has won a HK$2.55m contract from the Hong Kong government following the lifting of the temporary tendering suspension. 

Continue reading... | 22/07/2019

Ultimate Sports Group

Ultimate Sports Group has raised £290,000 at 14.5p a share. 

Continue reading... | 22/07/2019

LiDCO Group

LiDCO Group has received approval in China for its LiDCOrapidhaemodynamic monitor. 

Continue reading... | 22/07/2019

All micro news

Browse by issue
All issues
Popular tags
All tags

betbrokers, financial, gold, health, leisure, media, mobile, resources, services, technology

AIM Micro feeds

Keep up to date with articles published at Subscribe to AIM Micro RSS Feeds